
Summit Therapeutics' stock tumbles again as FDA recommends new trial for lung-cancer drug
来源:Market Watch发布于 2026-11-17
Summit Therapeutics' stock tumbled again Tuesday after the Food and Drug Administration said the biotech company should run a new clinical trial for its experimental lung-cancer drug.
相关标的:SMMT
本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。